Here is the honest headline a medical clinic can give you before you spend a single dollar: most consumer GLP patches sit far closer to clever marketing than to science backed treatment, because the underlying biology does not support the core claim
What makes the trial different is its primary endpoint
In the future, we will link our findings to patient-level claims data to understand how prior authorization design affect medication initiation, adherence, and patient outcomes
Weight loss is great, but they still want a youthful face
All of the dynamics around GLP-1s, compounding shortage workarounds, and potential for DTC telehealth fallout I described last August seem to be playing out in 2025
Weight Management May support ongoing weight-management efforts for eligible patients when prescribed as part of a personalized treatment plan